The United States Securities and Exchange Commission (SEC) has declared that Biodexa Pharmaceuticals Plc's Form F-1 has become effective as of March 27, 2024, at 5:00 P.M. This form is typically used by non-U.S. companies for registering securities for offering in the United States. The effectiveness of the form indicates that Biodexa Pharmaceuticals, which is listed under the CIK number 0001643918 and has the file number 333-278040, has met the necessary regulatory requirements to proceed with its securities offering.

The United States Securities and Exchange Commission (SEC) has declared that Biodexa Pharmaceuticals Plc's Form F-1 has become effective as of March 27, 2024, at 5:00 P.M. This form is typically used by non-U.S. companies for registering securities for offering in the United States. The effectiveness of the form indicates that Biodexa Pharmaceuticals, which is listed under the CIK number 0001643918 and has the file number 333-278040, has met the necessary regulatory requirements to proceed with its securities offering.